TrialBritish journal of cancer2018

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.

Shirish Gadgeel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.